Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1002/vetr.2683
Twittear
Título: | Evaluation of heart fatty acid-binding protein as a biomarker for canine leishmaniosis |
Fecha de publicación: | 2023 |
Cita bibliográfica: | Veterinary Record 2023 May 20;192(10):e2683. |
Materias relacionadas: | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología CDU::6 - Ciencias aplicadas::63 - Agricultura. Silvicultura. Zootecnia. Caza. Pesca::636 - Veterinaria. Explotación y cría de animales. Cría del ganado y de animales domésticos |
Resumen: | Background: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid-binding protein (HFABP) is a biomarker of myocardial damage. Methods: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty-one dogs diagnosed with CanL and 10 healthy dogs were included. Results: HFABPc was not statistically different (p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin (r = -0.519; p = 0.03) and haematocrit (HCT) (r = -0.538; p = 0.02) was observed. No other significant correlation (p > 0.05) was observed with any other variable. Limitations: Many statistical tests were performed, and therefore, type I error cannot be ruled out. Conclusion: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease. |
Autor/es principal/es: | Casamián-Sorrosal, Domingo Barrera-Chacón, Rafael Fonfara, Sonia Cristobal-Verdejo, Jose Ignacio Talavera López, Jesús Belinchón-Lorenzo, Silvia Miró-Corrales, Guadalupe Caro-Vadillo, Alicia Duque, Francisco Javier |
Facultad/Departamentos/Servicios: | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Medicina y Cirugía Animal |
URI: | http://hdl.handle.net/10201/137940 |
DOI: | https://doi.org/10.1002/vetr.2683 |
Tipo de documento: | info:eu-repo/semantics/article |
Número páginas / Extensión: | 11 |
Derechos: | info:eu-repo/semantics/openAccess |
Descripción: | ©<2023>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the, Accepted, version of a Published Work that appeared in final form in Veterinary Record (VetRecord). To access the final edited and published work see: https://doi.org/10.1002/vetr.2683 |
Matería temporal: | 2023 |
Matería geográfica: | España |
Aparece en las colecciones: | Artículos: Medicina y Cirugía Animal |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
vetrec-2022-106986.R2_Proof_hi-3-25.pdf | Versión aceptada para publicación | 463,52 kB | Adobe PDF | Visualizar/Abrir Solicitar una copia |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.